Bio-Rad Laboratories, Inc. Clas Company profile
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. Its segments include Life Science and Clinical Diagnostics. Its Life Science segment markets and develops, manufactures and markets approximately 9,000 reagents, apparatus and laboratory instruments that serve a global customer base. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Its Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. It supplies approximately 3,000 different products that cover over 300 clinical diagnostic tests to the in vitro diagnostics (IVD) test market.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Bio-Rad Laboratories, Inc. revenues increased 15% to $2.92B. Net income increased 12% to $4.25B. Revenues reflect Clinical Diagnostics segment increase of 16% to $1.52B, Life Science segment increase of 14% to $1.4B, Asia segment increase of 26% to $688.4M, United States segment increase of 13% to $1.13B, Europe segment increase of 10% to $946.9M.
Equity composition
Cl.A Common Stock $.0001 Par, 3/11, 80M auth., 22,845,116 issd. Insiders own 15.71%. Cl.B Common $.0001 Par, 20M auth., 5,156,673 issd. Insiders own 91.95%. PO 8/86, 400K shares @ $19 by Prudential Bache. 10/08, Exchange changed from AMEX to NYSE.
Latest shares articles



